Our objective is to determine the combined utility of CA-125, MIF, OPN and PROL in distinguishing ovarian cancer serum samples from healthy controls and compare its usefulness to CA-125 alone as a single biomarker. The gene discussed is SPP1; the disease is ovarian cancer.